ArticleFrontiers in physiology2025
Platelet-rich plasma improves pain and function in knee osteoarthritis: a retrospective study.
Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vitexin Alleviates Knee Osteoarthritis-Associated Cartilage Damage Associated with F3 Modulation.Genes · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to evaluate the efficacy of platelet-rich plasma (PRP) in treating knee osteoarthritis (KOA) and the effects of baseline characteristics and PRP intervention parameters on treatment outcomes. Methods: Overall, 140 individuals diagnosed with KOA who received PRP injections and completed a 6-month follow-up period were enrolled in this retrospective analysis. Knee pain and functional outcomes were assessed using the Visual Analog Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Based on the Minimal Clinically Important Difference (MCID) in outcomes, the participants were divided into effective and ineffective groups. Using multivariable logistic regression to explore factors influencing treatment outcomes, we compared the effective and ineffective groups to identify predictors of response to PRP therapy. Results: At 6 months, the median (IQR) VAS score significantly decreased from 66.5 (27) to 24 (34) (95% CI = -38 to -30.5), p < 0.001), and WOMAC scores improved from 29 (22) to 12 (14) (95% CI = -16.5 to -12), p < 0.001). Five mild adverse events were reported. Multivariate analysis indicated that only the number of injections significantly influenced VAS outcomes (OR = 4.285, 95% CI: 1.586-11.578, p = 0.004). Regarding WOMAC, multivariate analysis revealed that body mass index (BMI) (OR = 0.867, 95% CI: 0.755-0.995, p = 0.042) and disease duration (OR = 0.905, 95% CI: 0.784-0.989, p = 0.045) significantly affected outcomes. Age, sex, Kellgren-Lawrence (KL) grade, number of PRP injections, and injection frequency did not significantly impact WOMAC scores. Conclusion: PRP therapy is a safe and effective treatment option for KOA. In this 6-month follow-up investigation, we observed that the number of injections administered affected pain levels, while disease duration and BMI affected knee joint function. Insights from this study may facilitate patient selection and PRP treatment protocol optimization in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.